X-37

X-37 is a company that provides artificial intelligence (AI) drug discovery services and develops novel therapeutics. It was founded in 2019 by Abraham Heifets. The company is headquartered in San Francisco, California, United States.

X-37's uses an AI platform called AtomNet, which was developed by Atomwise, its parent company. The platform uses convolutional neural networks to develop new therapeutic compounds through its prediction of new molecule structures based on its analysis of three-dimensional representations of protein-ligand pairs. AtomNet is meant to be utilized after target and binding site selection have been conducted. X-37 is developing therapeutics intended to target ZAP-70 (autoimmune disease), PIM 3 (cancer), cGAS/STING (autoimmune disease and cancer), Factor XIIa (anticoagulation), and SHP2 (cancer). The company will partner with pharmaceutical companies after successful preclinical trials of these therapeutics.